Nowak, R. J., Coffey, C. S., Goldstein, J. M., Dimachkie, M. M., Benatar, M., Kissel, J. T., Wolfe, G. I., Burns, T. M., Freimer, M. L., Nations, S., Granit, V., Smith, A. G., Richman, D. P., Ciafaloni, E., Al-Lozi, M. T., Sams, L. A., Quan, D., Ubogu, E., Pearson, B., Sharma, A., Yankey, J. W., Uribe, L., Shy, M., Amato, A. A., Conwit, R., O'Connor, K. C., Hafler, D. A., Cudkowicz, M. E., & Barohn, R. J. (2022). phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 98, e376–e389. http://access.bl.uk/ark:/81055/vdc_100150541295.0x000060